Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma - A pilot study

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Positron Emission Tomography-Computed Tomography (PET-CT) is routinely used for staging and monitoring of human cancer patients and is becoming increasingly available in veterinary medicine. In this study, 18-fluorodeoxyglucose (18 FDG)-PET-CT was used in dogs with naturally occurring splenic hemangiosarcoma (HSA) to assess its utility as a staging and monitoring modality as compared to standard radiography and ultrasonography. Nine dogs with stage-2 HSA underwent18 FDG-PET-CT following splenectomy and prior to commencement of chemotherapy. Routine staging (thoracic radiography and abdominal ultrasonography) was performed prior to18 FDG-PET-CT in all dogs. When abnormalities not identified on routine tests were noted on18 FDG-PET-CT, owners were given the option to repeat a PET-CT following treatment with eBAT. A PET-CT scan was repeated on Day 21 in three dogs. Abnormalities not observed on conventional staging tools, and most consistent with malignant disease based on location, appearance, and outcome, were detected in two dogs and included a right atrial mass and a hepatic nodule, respectively. These lesions were larger and had higher metabolic activity on the second scans.18 FDG-PET-CT has potential to provide important prognostic information and influence treatment recommendations for dogs with stage-2 HSA. Additional studies will be needed to precisely define the value of this imaging tool for staging and therapy monitoring in dogs with this and other cancers.

Original languageEnglish (US)
Article numbere0172651
JournalPloS one
Volume12
Issue number2
DOIs
StatePublished - Feb 2017

Bibliographical note

Funding Information:
This work was supported in part by grant K01OD017242 (AB) from the Office of The Director, National Institutes of Health, grant AB15MN-002 from the National Canine Cancer Foundation (AB), a grant from the Masonic Cancer Center, University of Minnesota Sarcoma Translational Working Group (JFM, DAV, AB, JSK), the Randy Shaver Cancer Research and Community Fund (DAV), and a grant from GREYlong (JFM). The authors gratefully acknowledge generous support from the Angiosarcoma Awareness Foundation and donations to the Animal Cancer Care and Research Program of the University of Minnesota that helped support this project. JFM is supported in part by the Alvin S. and June Perlman Chair in Animal Oncology at the University of Minnesota. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other supporting organizations. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2017 Borgatti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma - A pilot study'. Together they form a unique fingerprint.

Cite this